20 November 2025
Support Casper and Deltaplan Alvleesklierkanker join forces
From November 2025, Stichting Overleven met Alvleesklierkanker (Support Casper) and Deltaplan Alvleesklierkanker will work together. The partnership also brings together the Dutch Pancreatic Cancer Group (DPCG), patient platform Living With Hope and MDL Fonds. By combining resources, knowledge and expertise, we can move faster and enable more research.
Innovative, effective treatment methods
Support Casper funds and promotes innovative, often experimental treatments, including immunotherapies such as dendritic cell therapy. The foundation's ambition is to help make effective, affordable pancreatic cancer treatments available by 2030.
Dr Nigel Kooreman, surgical oncologist at Erasmus MC, says: “The potential of immunotherapy for pancreatic cancer is still under-recognised. It has an important place alongside existing treatments.”
Improve existing treatment methods
Deltaplan Alvleesklierkanker focuses on improving existing care for people with pancreatic cancer. Across a national network of specialist centres, doctors, researchers and healthcare professionals work together to optimise treatment continuously. By pooling knowledge and comparing outcomes, they can refine surgical techniques, improve treatment schedules and protect patients' quality of life. The partnership also helps translate research findings into clinical practice more quickly, so that new insights can benefit patients throughout the Netherlands.
Dr Bert Bonsing, surgical oncologist at LUMC and chair of the DPCG, says: “The DPCG works to make existing treatments as effective as possible while preserving quality of life, and to maintain an internationally leading standard of care.”
Together against pancreatic cancer
Through this partnership, treatments shown to be effective in research funded by Support Casper can be introduced nationally through Deltaplan Alvleesklierkanker, making them available to all eligible patients. A national network of 15 treatment centres and university research groups gives innovative studies a greater chance of success. Working together also strengthens our ability to raise the funds needed for pancreatic cancer research.